Novel Therapies in Asthma: Long-Acting β2-Agonists Inhaled Corticosteroids

Evidence-based Respiratory Medicine

Volumn , Issue , 2007, Pages 217-230

  Marks, Nicola A ^a   Ind, Philip W ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Anti immunoglobulin E; Combination inhalers; Inhaled corticosteroids; Leukotriene antagonists; Novel therapies in asthma

Indexed keywords

EID: 84889360401     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987377.ch17     Document Type: Chapter

References (55)

1. Walters EH, Walters JAE, Gibson MDP. Inhaled long acting b agonists for stable chronic asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, John Wiley & Sons, 2004.
2. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroids or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-73.
3. Knox AJ. The scientific rationale of combining inhaled glucocorticoids and long acting b2 adrenoceptor agonists. Curr Pharm Des 2002; 8:1863-9.
4. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 mcg and fluticasone propionate 250 mcg in the Diskus device for the treatment of asthma. AmJ Respir Crit Care Med 2000; 161:527-34.
5. Van Noord JA, Lilli H, Carrillo J, Davies P. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500mg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus in patients with moderate to severe asthma. Clin Drug Invest 2001; 21:243-55.
6. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100mg twice daily) when administered via a chlorofluorocarbon-free metered dose or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95:136-46.
7. Kavaru M, Melamed J, Gross G et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomised, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 150:1108-16.
8. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112:29-36.
9. Jenkins C, Woolcock AJ, Saarelainen P, Lundback B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250mg twice daily in treating moderate to severe asthma. Respir Med 2000; 94:715-23.
10. Busse W, Koenig SM, Oppenheimer J et al. Steroid-sparing effects of fluticasone propionate 100mg and salmeterol 50mg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250mg administered twice daily. J Allergy Clin Immunol 2003; 111:57-65.
11. Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18:262-8.
12. Lalloo UG, Maloolepszy, Kozma D et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123:1480-7.
13. Bateman ED, Bantje TA, Joao Gomes M et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. AmJ Respir Med 2003; 168:275-81.
14. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than lowdose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088-95.
15. Calhoun WJ, Nelson HS, Nathan RA et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting b2-agonists alone. Am J Respir Crit Care Med 2001; 164:759-63.
16. Pearlman D, White M, Lieberman A. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002; 88:227-35.
17. Ringdal N, Eliraz A, Pruzinec P et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2001; 97:23-41.
18. Bateman ED, Britton M, Carrillo J. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16:193-201.
19. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone (50/500mg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93:876-84.
20. Ankherst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16:147-51.
21. Kirby S, Falcoz C, Daniel MJ, Milleri S. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56:781-91.
22. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. AmRev Respir Dis 2004; 170:836-44.
23. Leuppi JD, Salzberg M, Meyer L et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003; 133:302-9.
24. Stallberg B, Olsson P, Jorgensen LA, Lindmarck N, Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57:656-61.
25. FitzGerald JM, Sears MR, Boulet LP et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003; 10:427-34.
26. Ind PW, Haughney J, Price D, Rosen J-P, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004; 98:464-75.
27. Canonica GW, Castellani P, Cazzola M et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther 2004; 17:239-47.
28. Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003; 97:323-30.
29. Aalbers R, Backer V, Kava TTK et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20:225-40.
30. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999; 82:257-65.
31. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. AmJ Respir Crit Care Med 2001; 164:1392-7.
32. Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P on behalf of the Flow Research Group. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 2002; 57:791-8.
33. Lundback B, Jenkins C, Price MJ, Thwaites RMA. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 mg twice daily and budesonide 800mg twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000; 94:724-32.
34. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Costeffectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics. 2002; 20:909-18.
35. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21:951-89.
36. Rosenhall I, Borg S, Andersson F, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract 2003; 57:662-7.
37. Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-34.
38. Boulet L-P, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835-40.
39. Fahy JV, Cockroft DW, Boulet L-P et al. Effect of aerolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. AmJ Respir Crit Care Med 1999; 160:1023-7.
40. Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 study group. N Engl J Med 1999; 341:1966-73.
41. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
42. Solèr M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
43. Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:36-46.
44. Buhl R, Solèr M, Matz J et al. Omalizumab provides long-term control in patients with moderate to severe allergic asthma. Eur Respir J 2002; 20:73-8.
45. Buhl R, Hanf G, Solèr M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20:1088-94.
46. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378-86.
47. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
48. Flood-Page PT, Menzies-Gow, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
49. Kips JC, O'Connor BJ, Langley SJ et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma AmJ Respir Crit Care Med 2003; 67:1655-9.
50. Chapman KR, Ringdahl N, Backer V, Palmqvist M, Sarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250mg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6:45-51.
51. Johansson G, McIvor RA, Purello D'Ambrosio F, Gratziou C, James MH. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Invest 2001; 21:633-42.
52. Michils A, Peche R, Verbraeken J et al. SURF study: real-life effectiveness of budesonide/formoterol adjustable maintenance dosing. Allergy Clin Immunol Int 2003; 1:2-39.
53. Holgate ST, Chuchalin AG, Hébert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-8.
54. Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-17.
55. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma (ETOPA). Allergy 2004; 59:701-8.